'All In' For a Huge Pot: The PROWESS-SHOCK Tria: for Refractory Septic Shock

摘要

Drotrecogin alfa (activated) [DAA], or recom-binant human activated protein C (rhAPC), has been approved for therapy of severe sepsis and septic shock for six years, but controversy persists as to its efficacy and safety. Only the pivotal randomized, controlled trial (RCT) [PROWESS] has shown evidence of efficacy, and the risk of complications is recognized, especially hemorrhage.